StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Allogene Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Allogene Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $114.09M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$22.00K-76.8%
FY2023Dec 31, 2023$95.00K-39.1%
FY2022Dec 31, 2022$156.00K-99.9%
FY2021Dec 31, 2021$114.09M–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.64M–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$22.00K-26.7%
Q4 FY2023Dec 31, 2023$21.00K-19.2%
Q3 FY2023Sep 30, 2023$22.00K-18.5%
Q2 FY2023Jun 30, 2023$22.00K-65.6%
Q1 FY2023Mar 31, 2023$30.00K-23.1%
Q4 FY2022Dec 31, 2022$26.00K-100.0%
Q3 FY2022Sep 30, 2022$27.00K-44.9%
Q2 FY2022Jun 30, 2022$64.00K+45.5%
Q1 FY2022Mar 31, 2022$39.00K-99.9%
Q4 FY2021Dec 31, 2021$75.65M–
Q3 FY2021Sep 30, 2021$49.00K–
Q2 FY2021Jun 30, 2021$44.00K–
Q1 FY2021Mar 31, 2021$38.35M–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–

More Allogene Therapeutics figures

See a number that looks wrong?